DNLI - Kapitalisasi marang volume dodolan Denali
The P/S ratio dynamics for Denali Therapeutics (DNLI) on the GURU.Markets chart are based on the outsourcing of trials via external contractors, with the 141.70 value reflecting the current metric. Growth is driven by partnerships with pharma behemoths to overcome blood-brain barriers, while the success of the scientific pipeline is guaranteed by strict adherence to cold chain logistics for biomaterials.
Rincian analitis perusahaan Denali Therapeutics Inc (DNLI)
- rega saham lan konsensus proyeksi valuasi:
- statistik kapitalisasi pasar:
- informasi kapitalisasi buku:
- statistik kawajiban utang lan likuiditas:
Rasio Kabeh Utang marang Dana Pribadi Denali Therapeutics|DNLI - Utang jangka dawa marang modal|Utang jangka cendhak marang modal Denali Corp|DNLI - Utang perusahaan|Rasio utang-utang marang kapitalisasi buku Denali Therapeutics Inc|DNLI - Utang jangka dawa perusahaan|Utang jangka cendhak Denali Therapeutics|Rasio cepet denalitherapeutics.com
- informasi bathi lan kelipatan valuasi:
DNLI - Penghasilan resik|Bathi resik mangsa ngarep Denali Therapeutics|DNLI - Pangali P/E|Kapitalisasi marang proyeksi bathi Denali|DNLI - Pangali PEG|Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Denali Therapeutics Inc|DNLI - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi resik saben saham sajrone patang kuartal pungkasan Denali Therapeutics|DNLI - Bathi resik saben saham (EPS TTM)|Wutah bathi saben saham taun-ka-taun sajrone 12 wulan pungkasan denalitherapeutics.com|DNLI - Wutah bathi saben saham ing taun lumaku|Proyeksi kacepetan wutah bathi saben saham kanggo taun ngarep Denali Therapeutics
- rincian pendapatan lan dodolan emiten:
Analisis fundamental perusahaan:denalitherapeutics.com - DNLI
The P/S multiple reflects the market value of a business relative to its annual revenue, allowing for an assessment of the asset's overvaluation by comparing current capitalization with historical extremes. By analyzing the price-to-sales multiple, an investor can determine the fairness of the valuation of Denali Therapeutics (DNLI), taking into account the potential of the blood-brain barrier drug delivery platform and expected payments from strategic partners.
Perusahaan pesaing
BIIB (biogen.com) - Rasio kapitalisasi pasar marang pendapatan|Neurocrine Biosciences, Inc. - Kapitalisasi marang pendapatan|Kapitalisasi marang volume dodolan RGC (Regencell Bioscience Ltd)|Axsome Therapeutics Inc - Multiplikator P/S|Rasio kapitalisasi pasar marang pendapatan ACAD (ACADIA Corp)|XENE: Multiplikator P/S|Rega marang dodolan vikingtherapeutics.com (VKTX)|Rasio rega marang pendapatan Supernus|CPRX: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S HRMY|Multiplikator P/S Biohaven Corp (BHVN)|Rasio rega marang pendapatan Amylyx Pharmaceuticals AMLX|TRVI (trevitherapeutics.com) - Rasio rega marang dodolan|Praxis Precision Medicines, Inc. - Multiplikator P/S|Rega marang dodolan Anavex|CBLL (CeriBell Corp) - Kapitalisasi marang pendapatan|Prothena Corp (PRTA) - Multiplikator P/S|Kapitalisasi marang pendapatan ALEC|ANNX (annexonbio.com) - Kapitalisasi marang volume dodolan|Multiplikator P/S OMER|Koefisien rega marang pendapatan Neurogene Inc|Multiplikator P/S ACIU (AC Immune Corp)|VYGR - Kapitalisasi marang pendapatan|NMRA - Rasio rega marang pendapatan|Koefisien rega marang pendapatan scilexholding.com SCLX|TVGN: Multiplikator P/S|Rasio kapitalisasi marang pendapatan ACOG|Rasio rega marang pendapatan Cognition Therapeutics, Inc.|Rasio kapitalisasi marang pendapatan IKT (Inhibikase Pharma)|Rasio rega marang pendapatan Cassava Sciences, Inc. (SAVA)|Rasio rega marang pendapatan ASRT (assertiotx.com)|Multiplikator P/S COYA (Coya Therapeutics)|Koefisien rega marang pendapatan VistaGen Therapeutics, Inc. (VTGN)|OVID - Rasio rega marang pendapatan|ABOS (Acumen Pharmaceuticals, Inc) - Rasio kapitalisasi marang pendapatan|CRVO: Multiplikator P/S|Rega marang dodolan Alterity Therapeutics Limited (ATHE)|Kapitalisasi marang pendapatan CLNN|Multiplikator P/S PepGen Corp|Rasio rega marang pendapatan Jupiter Neurosciences (JUNS)|RLMD (Relmada Corp) - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Annovis Bio, Inc. ANVS|Grace Therapeutics Inc (GRCE) - Rega marang dodolan|Firefly Neuroscience - Multiplikator P/S|KLTO (Klotho Neurosciences Inc) - Rasio kapitalisasi marang pendapatan|NRSN: Multiplikator P/S|Rega marang dodolan Reviva Pharmaceuticals, Inc. (RVPH)|Rasio rega marang pendapatan MetaVia Inc.|Rasio kapitalisasi marang pendapatan NRXS (neuraxis.com)|Multiplikator P/S HSDT|Multiplikator P/S passagebio.com (PASG)|Rasio rega marang pendapatan Neuphoria Therapeutics NEUP|Minerva - Rasio rega marang pendapatan|Athira Pharma, Inc. - Multiplikator P/S|Koefisien rega marang pendapatan addextherapeutics.com ADXN|ALZN (alzamend.com) - Kapitalisasi marang pendapatan|Cyclerion Therapeutics, Inc. - Rasio kapitalisasi pasar marang pendapatan|Kapitalisasi marang pendapatan PTIX|KTTA (Pasithea) - Kapitalisasi marang volume dodolan|Multiplikator P/S CRGT|ATXI (avenuetx.com) - Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S BCLI (BrainStorm Cell Therapeutics)|Cara Therapeutics Inc. (CARA) - Rega marang dodolan|CHRO - Rasio rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan ELYM (Eliem Therapeutics)|ITCI: Multiplikator P/S|longboardpharma.com (LBPH) - Multiplikator P/S|Rasio rega marang pendapatan Marinus Pharmaceuticals, Inc.|NKGen Biotech Inc - Rasio rega marang dodolan|Multiplikator P/S NRBO|SAGE - Rega marang dodolan|Synaptogenix, Inc. - Kapitalisasi marang pendapatan|Multiplikator P/S trevena.com TRVN|VIGL: Kapitalisasi marang pendapatan|anewmeds.com - Kapitalisasi marang volume dodolan|CERE: Multiplikator P/S
